Jobs
-
Biohaven Pharmaceutical has announced that it met with the FDA following completion of Phase 2 clinical trials of its intranasal vazegepant (BHV-3500) for the treatment of migraine and is ready to advance the 10 mg… Read more . . .
-
Following up on the announcement that RDD 2020 would be replaced by a digital version of the meeting due to the COVID-19 pandemic, meeting organizers have now provided details on registration and on how the… Read more . . .
-
Nephron Pharmaceuticals CEO Lou Kennedy spoke to local reporters in the company’s home state of South Carolina on March 17, 2020, describing the company’s efforts to increase production of its inhalation solutions and suspensions to… Read more . . .
-
The UK Medicines and Healthcare products Regulatory Agency (MHRA) and Health Research Authority (HRA) have expedited approvals for a Phase 2 trial of Synairgen’s SNG001 nebulized interferon-beta-1a for the treatment of COVID-19, the company said. According… Read more . . .
-
Montreal-based Pharmascience has announced the launch of its pms-fluticasone propionate/salmeterol DPI in Canada for the treatment of asthma and COPD. The company says that the DPI uses the same device as Advair Diskus. According to… Read more . . .
-
Inhaled drug developer MannKind Corporation has announced that it “is committed to joining the global effort to overcome the COVID-19 crisis” and as a result “that it is adjusting research and development resources that were reserved… Read more . . .
-
Insmed has announced its submission of a new drug application to Japan’s Ministry of Health, Labour and Welfare (MHLW) for Arikayce amikacin liposome inhalation suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium… Read more . . .
-
Beyond Air said that it has submitted an investigational device exemption (IDE) to the FDA seeking to use its cylinder-free LungFit BRO inhaled nitric oxide (iNO) delivery system for the treatment of COVID-19. Beyond Air has been developing… Read more . . .
-
Due to public gathering and travel restrictions imposed in response to the COVID-19 pandemic, the organizers of RDD 2020 have made the decision to cancel the RDD 2020 conference that was scheduled to take place… Read more . . .
-
According to the FDA, three DPIs marketed by Sunovion in the US have been discontinued as of March 10, 2020. Sunovion acquired the US rights to Utibron (indacaterol/glycopyrrolate) Neohaler, Seebri (glycopyrrolate) Neohaler, and Arcapta (indacaterol)… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland